Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’s NASH Chief: Our Strategy Is Combos With Tropifexor As ‘Backbone’

Executive Summary

Novartis's broad but early-stage NASH pipeline will use FXR agonist tropifexor as its keystone for developing combination therapies with outside partners.

You may also be interested in...



Conatus Accepts Defeat For Emricasan In NASH

After multiple Phase IIb trial failures, Conatus says it will fulfill contractual obligations and consider strategic alternatives. Partner Novartis was already focused on other candidates and partnerships in NASH.

NASH News & Notes From The European Liver Meeting

Non-alcoholic steatohepatitis (NASH) was a focal point of EASL’s conference. Madrigal becomes the fifth company into Phase III in NASH, but Viking’s competing THR agonist is progressing also.

Novartis Dives Into Inflammasome Pool With IFM Tre Purchase

The Swiss major has bought a US biotech that specializes in targeting the NLRP3 pathway in a deal valued at up to $1.58bn.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125060

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel